Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection

Following a European review, the product information for VEGF pathway inhibitors has been updated to include a warning about the risk of aneurysm and artery dissection and to recommend carefully considering these risks before starting treatment in patients with known risk factors

Source:

Medicines and Healthcare products Regulatory Agency